Physician profile
David Collymore
NPI 1023000353
$3,032.44
in general payments reported to CMS, 2019-2025
12 companies · $1,301 in 2025
The $1,301 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $105 · 2021: $18.97 · 2022: $24.58 · 2023: $461 · 2024: $896 · 2025: $1,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,657.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $885.21 | 2022-2025 | Apretude, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $638.97 | 2019-2025 | Yeztugo, Biktarvy |
| Acadia Pharmaceuticals INC | $325.71 | 2024 | Nuplazid |
| Braeburn INC. | $242.86 | 2025 | Brixadi |
| Alkermes, INC. | $235.60 | 2025 | Lybalvi, Vivitrol |
| Exact Sciences Corporation | $165.67 | 2024-2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $153.27 | 2019 | |
| Neurocrine Biosciences, INC. | $124.77 | 2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $120.97 | 2025 | Invega Sustenna |
| Abbvie INC. | $48.19 | 2020 | |
| Merck Sharp & Dohme LLC | $46.79 | 2019-2021 | |
| Janssen Biotech, INC. | $44.43 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Collymore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.